Back to Search Start Over

Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors

Authors :
Lin Zhou
Yicong Wan
Lin Zhang
Huangyang Meng
Lin Yuan
Shulin Zhou
Wenjun Cheng
Yi Jiang
Source :
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116733- (2024)
Publication Year :
2024
Publisher :
Elsevier, 2024.

Abstract

The introduction of PARP inhibitors (PARPis) and immune checkpoint inhibitors (ICIs) has marked a significant shift in the treatment landscape for solid tumors. Emerging preclinical evidence and initial clinical trials have indicated that the synergistic application of PARPis and ICIs may enhance treatment efficacy and potentially improve long-term patient outcomes. Nonetheless, how to identify specific tumor types and molecular subgroups most likely to benefit from this combination remains an area of ongoing research. This review thoroughly examines current studies on the co-administration of PARPis and ICIs across various solid tumors. It explores the underlying mechanisms of action, evaluates clinical efficacy, identifies potential responder populations, and delineates common adverse events alongside strategic management approaches. The aim is to offer a detailed understanding of this combination therapy, potentially guiding future therapeutic strategies for solid tumors.

Details

Language :
English
ISSN :
07533322
Volume :
175
Issue :
116733-
Database :
Directory of Open Access Journals
Journal :
Biomedicine & Pharmacotherapy
Publication Type :
Academic Journal
Accession number :
edsdoj.0c573b5b720547b7918ed471afe50407
Document Type :
article
Full Text :
https://doi.org/10.1016/j.biopha.2024.116733